You are here: Industry Insights > AbbVie

News List

Regenxbio, AbbVie close license and collaboration deal to develop RGX-314 Pharmaceutical-Business-Review
November 11, 2021
Biotechnology firm Regenxbio and AbbVie have closed the previously announced license and collaboration deal for the development and commercialisation of the former’s gene therapy, RGX-314.
AbbVie's Rinvoq cleared in EU for atopic dermatitis firstwordpharma
August 25, 2021
AbbVie announced Tuesday that the European Commission has expanded the label for Rinvoq (upadacitinib) to include treating moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.
AbbVie’s net revenues rise 33.9% in Q2 2021 pharmaceutical-technology
August 03, 2021
The full-year 2021 GAAP diluted EPS and adjusted diluted EPS guidance updated to $6.04 to $6.14 and $12.52 to $12.62, respectively.
AbbVie's 2Q Revenue up 34% contractpharma
August 02, 2021
New immunology assets Skyrizi and Rinvoq contribute more than $1 billion of combined sales in the quarter.
Calico and AbbVie: Google-backed partnership re-commits to anti-ageing mission pharmaceutical-technology
July 30, 2021
Google-backed Calico Labs is an R&D company with quite the mission: combatting the ageing process. Founded in 2013, and with former Genentech CEO Arthur Levinson at the helm, the company hopes to uncover the biological pathways of ageing and the ...
New Data Presented on the Safety and Efficacy of Investigational AGN-190584 as a Potential Novel Treatment for Presbyopia, a Common and Progressive Eye Condition drugs
July 30, 2021
Allergan today announced new data, including the full results from the Phase 3 GEMINI 1 clinical study, evaluating the efficacy, safety and tolerability of investigational AGN-190584 ophthalmic solution for the treatment of presbyopia.
AbbVie and Calico extend partnership on drugs for age-related diseases pharmaceutical-technology
July 29, 2021
AbbVie and Calico Life Sciences have expanded their partnership to discover, develop and commercialise novel treatments for age-related diseases such as neurodegeneration and cancer.
Collaboration between AbbVie, Biogen and Pfizer creates world's largest browsable resource linking rare protein-coding genetic variants to human health and disease worldpharmanews
July 16, 2021
The access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie, Biogen Inc. and Pfizer.
Big pharma collaborates on free resource linking genetic variants to human disease europeanpharmaceuticalreview
July 12, 2021
The collaborative work has produced the largest browsable resource linking rare protein-coding genetic variants to human health and disease that will accelerate targeted drug development.
Collaboration Between AbbVie, Biogen and Pfizer Creates World’s Largest Browsable Resource Linking Rare Protein-Coding Genetic Variants to Human Health and Disease firstwordpharma
July 09, 2021
Today, access to the world's largest browsable resource linking rare protein-coding genetic variants to human health and disease was launched through a genetic exome sequence analysis collaboration between AbbVie (NYSE: ABBV), Biogen Inc. (Nasdaq: BIIB) a

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page